The aim of this study was to perform a population pharmacokinetic analysis of tacrolimus in Mexican adult kidney transplant patients to analyse the influence of clinical and genetic covariates to propose a dosage regimen. Kidney transplant patients (>18 years old) receiving oral tacrolimus treatment were included in the current study. The population pharmacokinetic model was built using a one-compartment model and the First Order Conditional Estimation method with Interaction (FOCEI via NONMEM v.7.3.). A total of 600 tacrolimus trough blood concentrations from 52 kidney transplant patients were analysed. Tacrolimus clearances were 26, 18.8 and 12.3 L/h, for patients with genetic polymorphisms CYP3A5*1*1, *1*3 and *3*3, respectively. The influence of haematocrit was inversely related to tacrolimus clearance, following an allometric power function. Total volume of distribution was 604 L.
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Interindividual variability associated with tacrolimus clearance and distribution volume for the final model was 33 and 63%, respectively, with a residual error of 2.5 ng/mL. Relative bioavailability was calculated between generic formulations A (0.53) and B (1) of tacrolimus. Internal validation was performed through bootstrap analysis to evaluate the stability of the final model; external validation was performed in a new group of patients (n = 13) to estimate residual errors on basic (57.8%) and final (34.8%) models. Finally, stochastic simulations were performed to propose a dosage regimen based on haematocrit, CYP3A5 genotype and generic formulation of tacrolimus. A stable and predictive population pharmacokinetic model of tacrolimus was developed for Mexican adult kidney transplant patients; additionally, the proposed dosage regimen of tacrolimus should be prospectively validated.
| INTRODUCTION
Tacrolimus is a calcineurin inhibitor used as immunosuppressive treatment to avoid graft rejection for kidney transplant patients. A narrow therapeutic index has been reported (5-15 ng/mL) to ensure maximum efficacy and minimum toxicity. 1 Lower blood trough concentrations of tacrolimus increase the risk of rejection, and higher blood trough concentrations could result in gastrointestinal disorders and infections, as well as the development of hypertension or type 2 diabetes mellitus. 2, 3 After oral administration, tacrolimus distributes into red blood cells, showing a blood-to-plasma ratio of approximately 50% with a haematocrit of 45%, and the unbound fraction in the blood is <1%. This immunosuppressive drug is routinely measured as a total concentration in whole blood, although the unbound concentration is expected to mediate the pharmacological effect. 4 It has been shown that estimation of pharmacokinetics parameters based on the identification of genetic polymorphisms, that codes for enzymes that metabolize tacrolimus, may be useful to determine the initial oral dose of tacrolimus, minimizing the risk of under-or over-immunosuppression in the early stage of renal transplantation. 5 Tacrolimus is bio-transformed by O-demethylation, hydroxylation and/or oxidative metabolic reactions in the liver microsomes. Isozymes CYP3A4 and CYP3A5 from the cytochrome P450 family catalyse the tacrolimus metabolism. 6 A single nucleotide polymorphism (SNP) in position 6989 (A>G), at intron 3 of isoform CYP3A5, produces stop signalling that results in a truncated protein.
Homozygous patients with CYP3A5*3 are considered poor metabolizers for tacrolimus; thus, they need lower tacrolimus doses to achieve therapeutic blood concentrations than patients with CYP3A5*1*3 and CYP3A5*1*1 who need higher doses of this immunosuppressant based on the metabolic activity of the protein. 7 Tacrolimus is also metabolized by the most abundant isoform of cytochrome P450, CYP3A4 isoform, and it has been shown that SNP CYP3A4*22 at intron 6, position 15 389 (C>T), is related to requiring minor doses for tacrolimus, and up to 30% lower for kidney transplant patients, even if a heterozygous genotype is present. 8 Thus, the pharmacokinetics and pharmacogenetics of tacrolimus have an important role in the clinical practice because it would allow optimization of pharmacotherapy of this immunosuppressant. The aim of this study was to develop and validate a population pharmacokinetic model of tacrolimus in adult Mexican patients with renal transplant, and additionally to propose an a priori dosage regimen to optimize immunosuppressive therapy. open-source, S-based statistical software). 11, 12 The FirstOrder Conditional Estimation with interaction method (FOCEI) was used to estimate pharmacokinetic parameters. The precision of the parameter was estimated using the covariance step. Visual inspections of the tacrolimus blood concentration vs time profiles and the objective function value (OFV), calculated using likelihood-ratio tests, were used to determine the base model. Generic formulations were classified as A or B, and subsequently, their bioavailability was calculated based on blood concentrations. Due to the nature of the samples (pre-dose), the absorption rate was set to 1.04 h −1 , as estimated by Asberg et al. 13 Additive, proportional and exponential error models were tested on interindividual variability (CL and V) and residual error. Following model development, a total of 19 covariates were evaluated in a stepwise forward selection; significant covariates were combined in a full model to characterize tacrolimus CL. This was followed by backward elimination, and significant covariates were retained in the final model. The continuous covariates tested were age, weight, height, body mass index (BMI), serum creatinine, creatinine clearance (estimated using the Cockcroft and Gault equation with total body-weight 14 ) , glucose, BUN, haematocrit, urea and post-transplantation time. The categorical covariates evaluated were gender, concomitant administration of verapamil, acyclovir, or omeprazole, donor (living or cadaveric), tacrolimus generic formulation (A or B) and genetic polymorphisms of CYP3A4 and CYP3A5. Preliminary selection of covariates was performed with the stepwise covariate model (SCM) building tool of PsN. Covariate selection was guided using likelihood-ratio tests at a significance level of P < 0.05 for forward addition of covariates (ΔOFV>3.84); and P < 0.01 for backward elimination of covariates (ΔOFV>6.63). Diagnostic plots and comparisons of changes in the minimum OFV between the nested models were used to evaluate the covariates, as well as the biological plausibility of the results. Continuous covariates effects were introduced into the population model using linear, power or exponential functions; parameters were also centred to the median value of the continuous variables in the database (allometric function). Discrete covariates were introduced as described by Mould and Upton, 15 that is, 0 for women and 1 for men.
| Validation of the pharmacokinetic model
Internal validation was performed with bootstrapping, which was based on 1000 resamples generated from the original database and following the same structure of the final model. It was considered that the model was stable if the mean parameters estimated with the original database are found into the 2.5th and 97.5th percentiles built, with the databases generated by resampling technique. Additionally, the final pharmacokinetic model was externally validated with a new group of patients with similar characteristics to those included in the population study group. The performance of the population pharmacokinetic model was evaluated using a priori predictions. Tacrolimus concentrations of the validation group were compared with predicted values to estimate the precision of the final population model. The bias fit was evaluated via the mean prediction error (ME). Precision was estimated via the mean absolute prediction error (MAE) and the root mean square of the prediction error (RMSE). 16 Percentage of prediction error (PPE) was calculated as PPE = (predicted value − observed value)/observed value * 100. 17 
| Dosing recommendations
Stochastic simulations (n = 1000) were performed with the final population model for dose selection, considering covariates that influenced on tacrolimus CL. Typical patients were simulated to predict trough concentrations at a steady state, and different doses of tacrolimus were probed. Dosage regimens were chosen at the level of the higher percentage of patients who achieved a therapeutic level for each simulation performed.
3 | RESULTS
| Patients
A total of 52 kidney transplant patients, with a median of 71 post-transplant days (range 4-2730 days), were included in the development of the pharmacokinetic model. Clinical and anthropometric data of the patients are shown in Table 1 . Tacrolimus dosing ranged from 0.01 to 0.19 mg/ kg/d (median 0.08 mg/kg/d). A total of 600 tacrolimus trough blood concentrations were used to build the population pharmacokinetic model; a mean of 11 samples was registered for each patient (minimum 3 and maximum 29 samples per patient). Overall, the genotype CYP3A4*1*1 was the most frequent in this population, and none of the transplanted patients showed the homozygous genotype for polymorphic allele *22. For CYP3A5, most of the patients were poor metabolizers, showing the homozygous genotype CYP3A5*3, followed by the heterozygous genotype (CYP3A5*1*3), and the homozygous genotype CYP3A5*1 was less frequent in this population, as shown in Table 2 .
| Population pharmacokinetic model
A one-compartment open model with first-order elimination (ADVAN2 TRANS2 subroutines) was used to characterize tacrolimus plasma concentration vs time data. Based on graphical and visual inspections, proportional error model was selected to describe the interindividual variability associated with tacrolimus CL and V; the residual variability was modelled as a homoscedastic error model (additive).
The base model estimates a mean value of 20.1 L/h for tacrolimus CL and 1370 L of V, interindividual variability on CL and Vd was 46.4% and 74.4%, respectively, and residual error was 38.1% to a mean blood concentration of 8.9 ng/mL (0.3-28.6 ng/mL).
Haematocrit as a continuous covariate showed significant statistic influence on CL of tacrolimus and was included into the model, reducing the OFV in 10.8 units (P < 0.05), respective to the basic model. Patients with low haematocrit values (<25%) demonstrated increased tacrolimus CL when compared with patients with higher haematocrit values.
The categorical covariates that showed significant influence were the CYP3A5 genotype and the generic formulation of tacrolimus. The inclusion of the generic formulation covariate made it possible to calculate the relative bioavailability of generic formulation A in 53% with respect to generic formulation B. Including this covariate in the model caused the greatest decrease in OFV (ΔOFV −320; P < 0.05). CYP3A5 genotype significantly affected tacrolimus CL (ΔOFV −20; P < 0.05); patients with the phenotype called as "normal" metabolizer (CYP3A5*1*1) were related to higher tacrolimus CL; patients with an "intermediate" metabolizer phenotype (CYP3A5*1*3) showed a mid CL of tacrolimus; and patients with a "poor" metabolizer phenotype (CYP3A5*3*3) showed a lower tacrolimus CL. The results of the model-building process are summarized in Table 3 .
The final model provided an explanation of 28.8% and 15% of interindividual variability for tacrolimus CL and V, respectively, and 25.2% of the residual error. The estimated parameters of the final covariate model are shown in Table 4 . Figure 1 shows basic goodness-of-fit plots for the base and final population pharmacokinetic models.
| Validation of the pharmacokinetic model
The results obtained from bootstrapping are summarized in Table 4 ; pharmacokinetic parameters (θ) corresponding to the final one-compartment open model are indicated as the median, and the 2.5th and 97.5th percentiles. The reported percentiles cover the mean values estimated for each parameter, reflecting the symmetry of the distribution and assuming stability for the final model.
External validation for the final model was performed in a data set of 72 tacrolimus trough blood concentrations from a new group of 13 adult patients with kidney T A B L E 1 Clinical and anthropometric data from patients included in the building of the population pharmacokinetic model (n = 52) and its external validation (n = 13) transplant. Figure 2 shows the observed and predicted blood concentrations of tacrolimus for this new validation study group with the final population pharmacokinetic model. The results of the performance evaluation are shown in Table 5 ; lower values for imprecision and bias are obtained with the final model, and the ME is distributed around zero. The PPE was higher in the base model (39%) than in the final model (4%) with residual errors of 57.8% (base model) and 34.8% (final model) considering a mean trough concentration of 8.5 ng/mL.
| Dose recommendations
Finally, stochastic simulations were developed to establish the dosing recommendation based on the final pharmacokinetic model. According to the performed simulations, patients displaying a low haematocrit value (<25%) require a higher tacrolimus dose to achieve the same blood concentration in the therapeutic range when compared to patients with a mid or high value of haematocrit (>25%). Another covariate included was the CYP3A5 genotype; patients with the CYP3A5*1*1 genotype need a major dose of tacrolimus because they present a higher tacrolimus CL in comparison with CYP3A5*1*3 and CYP3A5*3*3 genotypes. The generic formulations of tacrolimus were related to bioavailability; therefore, patients treated with generic formulation A must increase the dose of tacrolimus, since it has half of the bioavailability when compared to generic formulation B. Performed simulations were expected to reach a medium trough blood concentration of approximately 10 ng/mL of tacrolimus, considering the therapeutic range of 5 to 15 ng/ mL. The results of the dosage recommendations are shown in Table 6 .
| DISCUSSION
A population pharmacokinetic model clinically applicable to predict a priori blood trough concentrations of tacrolimus in kidney transplant patients has been developed; the Residual variability (ng/mL) 2.5 2.5 2.2 2.7 pharmacokinetic model includes three covariates (haematocrit, CYP3A5 genotype and generic formulation of tacrolimus) to describe tacrolimus CL and its bioavailability.
The influence of haematocrit on tacrolimus CL has been previously reported. Minematsu et al. 18 indicated that a decrease in haematocrit from 45% to 15% was related to a three times increase in tacrolimus CL. Staatz et al. 19 reported that tacrolimus CL increased up to 31.8 L/h when the haematocrit value was lower than 33%; for this reason, they conclude that it is important to consider haematocrit value when individualizing tacrolimus dosing, since this clinical parameter may vary with respect to time after transplantation. Moreover, Størset et al. 4 considered haematocrit to explain the residual variability associated with total blood concentrations; this was corroborated by Andreu et al. 20 who predicted tacrolimus concentrations based on haematocrit levels for a better fit of the final model. In the current study, haematocrit value was the only continuous covariate that influenced tacrolimus CL. Low haematocrit values presumably result in a reduced fraction of tacrolimus bound to erythrocytes and, consequently, an increased plasma fraction that is more readily metabolized mainly by cytochrome P450 in the liver. 21 Based on this finding, patients with low levels of haematocrit should receive higher doses of tacrolimus as stated in Table 6 and must be followed up routinely, since gradual increase in haematocrit after transplantation is expected. The CYP3A5 genotype is the other covariate that affects tacrolimus CL; the high frequency of polymorphic allele *3 (74%) allowed to demonstrate its influence on tacrolimus pharmacokinetics. Carriers of the CYP3A5*1*1 genotype have a higher CL (26 L/h) in comparison with CYP3A5*1*3 (18.8 L/h) and CYP3A5*3*3 (12.3 L/h) genotypes for patients with an average haematocrit level of 39.2%. The required dose of tacrolimus is higher in recipients with a functional enzyme (CYP3A5*1*1 genotype) than in patients with low functional enzymes (CYP3A5*1*3 and CYP3A5*3*3 genotypes). Several studies have found similar associations between CYP3A5 genotype and tacrolimus dose requirement, establishing that expressers of a functional enzyme require larger doses to maintain the same blood concentration at the therapeutic range than expressers of a non-functional enzyme. 7, 20, 22, 23 In some studies, CYP3A4*22 allele has been associated with requiring lower doses of tacrolimus to achieve therapeutic blood trough concentrations. 8, 24 The influence of CYP3A4*22 in tacrolimus pharmacokinetics could not be proven in this investigation; this may be related to the low frequency of this allele in Mexican population (1.9%).
The inclusion of the generic trademark refined the model fit by assigning a different value of bioavailability for each formulation. The disposition of this calcineurin inhibitor p.o. is susceptible to formulation manufacturing, affecting drug delivery and bioavailability. 25 An investigation by Jacobo-Cabral et al. 26 indicated that Limustin ® has a lower bioavailability when compared to an innovator product (Prograf ® ); moreover, Petan et al. 27 demonstrated that Framebin ® showed slower and incomplete drug dissolution, as well as low solubility, and the content varied widely when compared to the innovator product (Prograf ® ). For these reasons, it was decided that generic formulations, administered to patients included in the present study, had to be classified based on corresponding blood trough concentrations corrected by dose of tacrolimus to determine the relative bioavailability among generic formulations. This resulted in a higher bioavailability of Framebin ® than Limustin ® , demonstrating that generic formulations of tacrolimus are not interchangeable and switching between them will result in significant changes in blood concentrations; therefore, critical clinical attention and therapeutic monitoring are required. 28, 29 In summary, haematocrit value, CYP3A5 genotype and generic formulations were identified as covariates that significantly affect tacrolimus CL. The typical value of total tacrolimus CL was 12.3 ± 0.98 L/h for a patient with a median haematocrit of 39.2% and CYP3A5*3*3 genotype, the most common for this Mexican population. These results are similar to those reported by Woillar et al., 25 because in our population pharmacokinetic model the haematocrit and CYP3A5 genotype were associated with tacrolimus CL, resulting in that CYP3A5*3*3 clearance was approximately a half than CYP3A5*1*1.
Simulations performed with the final population pharmacokinetic model allowed the proposal of a dosage regimen for adult kidney transplant patients. This established that a patient with CYP3A5*1*1 genotype and low haematocrit value who uses generic formulation A needs major doses to achieve a therapeutic trough blood concentration of tacrolimus than patients with higher haematocrit values, administration of B formulation or carriers of CYP3A5*1*3/ CYP3A5*3*3 genotype. A similar dosage regimen was proposed by Bergmann et al., 30 based on the CYP3A5 genotype among an Australian population. However, proposed dosage regimen must be used carefully in CYP3A5*1*1 carriers, due to the low frequency found of this genotype in the study population.
One of the main limitations of the current study is that concentration-time data are retrospective data, we do not control the sampling or administration time of tacrolimus, and we assume that this could be an important factor that influences the residual variability and predictive error. Hence, dosing recommendations that have not yet been prospectively validated, and the results of stochastic simulations should be taken with caution. Nevertheless, the population pharmacokinetic model displayed a value of shrinkage linked to interindividual variability on CL of 6%, indicating the good quality of its building process, which could be related to an appropriate number of observations per patients analysed in this study. It has been established that a shrinkage lower than 20% indicates that relationships between the covariates and CL are real. 15 In conclusion, a population pharmacokinetic model was developed to describe the influence of haematocrit values and CYP3A5 genotype on tacrolimus clearance in Mexican patients with kidney transplant; considerations for generic formulations are also described.
The results of this investigation could be useful for a priori prediction of blood trough concentrations of tacrolimus, establishment and readjustment of dosage regimens of this immunosuppressant to minimize the presence of adverse effects by overdose and to reduce rejection and graft loss caused by under-dosing. Accordingly, the proposed dosage regimen of tacrolimus can be evaluated in later investigations to its clinical application.
